SHIM
CRDL

Stone House Investment Management’s Cardiol Therapeutics CRDL Stock Holding History

Stone House Investment Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$48 – 531
2025
Q1 		$48 Buy
+50
New +$61 ﹤0.01% 429
2024
Q4 		– Sell
-50
Closed -$99 – 118
2024
Q3 		$99 Hold
50
– – ﹤0.01% 372
2024
Q2 		$101 Buy
+50
New +$106 ﹤0.01% 374

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return

Stone House Investment Management's CRDL Position: Q2 2025 in Review

Stone House Investment Management sold out of Cardiol Therapeutics (CRDL) in Q2 2025, closing a stake of 50 shares — an estimated $48 sold.

Stone House Investment Management first reported a position in CRDL in Q2 2024 and held it in 3 quarters. The position peaked at $101 in Q2 2024. 38 funds tracked by Wall St. Rank hold CRDL as of Q2 2025.

  • Stone House Investment Management reported no remaining Cardiol Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stone House Investment Management sold 50 Cardiol Therapeutics shares in Q2 2025, an estimated $48.
  • Stone House Investment Management first reported a position in Cardiol Therapeutics in Q2 2024 and held it in 3 quarters.
  • Stone House Investment Management's Cardiol Therapeutics position peaked at $101 in Q2 2024.
  • 38 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2025.

Based on Stone House Investment Management's 13F filing for Q2 2025, filed 6 Aug 2025.